What is Contraline?
Founded in 2015 and based in Charlottesville, Virginia, Contraline is a medical device innovator dedicated to expanding the landscape of male contraception. The company is currently developing ADAM, a non-hormonal, long-lasting contraceptive device that utilizes advanced hydrogel technology to achieve occlusion of the vas deferens. By addressing a significant gap in the reproductive health market, Contraline is transitioning from early-stage research into a scaling enterprise, leveraging deep-tech engineering to provide safe and effective alternatives for men and couples globally.
How much funding has Contraline raised?
Contraline has raised a total of $113.7M across 5 funding rounds:
Angel/Seed
$2.3M
Series A
$10.7M
Other Financing Round
$1M
Other Financing Round
$7.2M
Series B
$92.5M
Angel/Seed (2017): $2.3M, investors not publicly disclosed
Series A (2021): $10.7M led by ShangBay Capital, Rhia Ventures, MBX Capital, Graphene Ventures, Metaplanet, Smith Ventures, and Founders Fund
Other Financing Round (2022): $1M supported by Male Contraceptive Initiative
Other Financing Round (2022): $7.2M featuring Rhia Ventures and GV
Series B (2026): $92.5M backed by BVF Partners, GV, Lumira Ventures, and RA Capital Management
Key Investors in Contraline
BVF Partners
BVF Partners is a San Francisco-based private investment partnership specializing in fundamentally-driven public and private biotechnology investments with a focus on long-term value creation.
GV
GV is a global venture capital firm that invests across multiple stages and sectors, with a strong emphasis on life sciences, frontier technology, and enterprise solutions.
Lumira Ventures
Lumira Ventures is a prominent life sciences venture capital firm that partners with healthcare innovators to develop and commercialize impactful medical devices and biotherapeutics.
What's next for Contraline?
With the successful closure of its latest financing round, Contraline is poised to intensify its clinical trial operations and refine its manufacturing processes for the ADAM device. The strategic backing from specialized life sciences investors provides the necessary runway to navigate complex regulatory pathways and prepare for potential commercialization. As the company moves forward, the focus will remain on validating the long-term efficacy and safety of its hydrogel technology, while simultaneously building the infrastructure required to bring this disruptive medical device to the global market.
See full Contraline company page
